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BACKGROUND: The cancer stem cell hypothesis suggests that neoplastic clones are maintained exclusively by a small subpopulation of
cells, which have indefinite proliferation and differentiation potentials and give rise to phenotypically diverse cancer cells. Cancer stem
cells have been isolated by their ability to efflux Hoechst 33342 dye and are referred to as the ‘side population’ (SP).
METHODS AND RESULTS: The Hoechst efflux assay was used to isolate and characterize the SP from murine D121 lung carcinoma cells.
Here, we demonstrated that D121-SP cells contain cancer stem cell characteristics, that is, upregulation of the transcription factors
SOX2 and Oct 4 in D121-SP cells. In addition, the migration of D121-SP was decreased, and apoptosis of D121-SP was upregulated
following knocking down of SOX2 in D121 cells. Importantly, downregulation of SOX2 in D121 cells markedly suppressed their
metastatic potential in syngeneic mice.
CONCLUSIONS: These results suggest that the SP is an enriched source of lung tumour cells with stem cell properties and that SOX2
has an important role in maintaining stem cell properties and functions that may be a potential target for effective lung cancer therapy.
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The cancer stem cell hypothesis suggests that neoplastic clones are
maintained exclusively by a small subpopulation of cells, which
have an indefinite proliferation and differentiation potential and
give rise to phenotypically diverse cancer cells (Reya et al, 2001;
Pardal et al, 2003). The limited numbers of CSCs in the tumour cell
population and their specific phenotypes are considered respon-
sible for their escape from conventional cancer therapies resulting
in disease relapse (Pardal et al, 2003). These CSCs were initially
identified in haematologic tumours, such as leukaemia (Bonnet
and Dick, 1997) and subsequently found in various solid
malignancies such as brain, breast, prostate, and lung cancinoma
(Singh et al, 1990; Al-Hajj et al, 2003; Kim et al, 2005; Xin et al,
2005). A useful approach for identification and purification of
CSCs, specifically in the absence of suitable surface marker
expression is based on the phenomenon that stem cells have the
specific ability to efflux lipophilic, fluorescent dyes such as
Hoechst 33342. The efflux of this dye was found to be correlated
with ABC transporters, in particular ABCG2, (Zhou et al, 2001)
which could be specifically inhibited by Ca
þþ-channel blockers.
This population of cells, low in Hoechst dye, was designated SP
and was first observed in haematopoietic tumour where the bone
marrow was greatly enriched in stem cells. (Spangrude and
Johnson, 1990; Goodell et al, 1996). In addition, this dye efflux
method was also applied to identify SP cells with stem cell
properties in a variety of tissues such as mammary gland, skin,
brain, and liver (Wulf et al, 2003; Kim and Morshead, 2003;
Challen and Little, 2006).
In our previous studies, we successfully used this Hoechst 33342
dye method to isolate SP with CSC properties from murine 4T1
breast carcinoma and NXS2 neuroblastoma cell lines and
transplanted them into the immune-competent microenvironment
of syngeneic mice. These SP cells not only displayed characteristics
of stem cell markers, but also exhibited increased resistance to
chemotherapy when compared with non-SP cells. Most impor-
tantly, SP cells showed a markedly higher repopulation and
tumourgenic potential in vivo (Kruger et al, 2006).
A number of links were recently found between SOX transcrip-
tion factors and cancer (Dong et al, 2004). Thus, SOX2 was
reported to be an immunogenic antigen in 41% of small cell lung
cancer patients (Gure et al, 2000). Also, SOX2 was involved in later
events of carcinogenesis such as invasion and metastasis of
pancreatic (Sanada et al, 2006) and prostate (Sattler et al, 2000)
cancers. In addition, SOX2 was expressed in 43% of basal cell like
breast carcinomas (Rodriguez-Pinilla et al, 2007). Recently,
molecular mechanisms governing the oncogenic potential of
SOX2 in breast cancer were elucidated, indicating that this
transcription factor promotes cell proliferation and tumourigen-
esis by facilitating the G1/S transition and through its transcrip-
tional regulation of the CCNDS gene in breast cancer cells.
In addition, b-catenin was identified as a transcription factor
particular for SOX2 (Garcia-Lavandeira et al, 2009). Apparently,
SOX proteins, including SOX2, bind to specific DNA sequences by
means of their highly conserved high mobility group domain in
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sfunctioning as transcription factors to activate or repress target
gene expression (Kamachi et al, 2000; Wilson and Koopman,
2002). In fact, numerous transcription factors from a wide range of
gene families were found to partner with SOX proteins (Kamachi
et al, 2000; Wilson and Koopman, 2002) and such partnerships
were found to be crucial in determining the functional specificity
of SOX proteins. Another important factor, in this regard, is the
identification of downstream targets of SOX proteins. Thus,
transcriptional regulatory networks consist of functional interac-
tions between regulatory genes and a much larger set of
downstream target genes. The network of SOX2: Oct 4 target
genes include among others SOX2, Oct 4, Nanog, FGF-4, UTF1,
Fbx15 and Lefty1. Furthermore, each of these target genes is
substantially downregulated upon differentiation of both embryo-
nic stem cell (ESs) and embryonic cell, due to the downregulation
of SOX2 and Oct 4 (Yuan et al, 1995; Chambers et al, 2003). Given
the importance of SOX2/Oct 4 target genes during development, it
is no surprise that their expression is tightly controlled. Thus, even
small changes in Oct 4 levels can drastically alter cell fate. For
example, a two-fold increase in Oct 4 levels caused ES cells to
differentiate into endoderm and mesoderm, whereas knockdown
of Oct 4 induced ES cells to differentiate into trophectoderm-like
cells (Niwa et al, 2000). Clearly, the consequences of altering the
level of Oct 4 have provided useful insights into the developmental
potential of ES and EC cells. However, much less attention has
been placed thus far on understanding how altering the levels of
SOX2 influences cell fate. Although knockdown of SOX2 causes
ES cells to differentiate (Chew et al, 2005; Rodda et al, 2005), there
are few reports describing how elevating SOX2 levels influences the
regulation of SOX2/Oct 4 target genes as well as generation
of CSCs.
Here, we demonstrate that the CSC concept can also be applied
to a mouse lung tumour model by identifying SP retaining low
Hoechst 33342 dye in a murine D121 non-small cell lung
carcinoma cell line. Importantly, this SP displays stem cell
characteristics in vitro, which can be considerably enriched to
highly express transcription factor SOX2. Importantly, siRNA-
mediated knockdown of SOX2 in CSCs significantly suppresses
tumour growth and experimental pulmonary metastases of
D121 non-small cell lung tumour cells transplanted into syngeneic
C57/BL6 mice.
MATERIALS AND METHODS
Animal cell lines and reagents
The C57BL/6 mice, 6–8 weeks of age, were purchased from The
Jackson’s Laboratory (Bar Harbor, ME, USA). All animal experi-
ments were performed according to National Institutes of Health
guidelines. The murine D121 non-small lung carcinoma cell line
was generously provided by Dr Lea Eisenbach (Weizmann
Institute of Science, Rehovot, Israel). The IFN-g and MHC-I
antibody were purchased from Invitrogen (Invitrogen, Carlsbad,
CA, USA).
Flow cytometry analysis and cell sorting
We stained 1 10
6 tumour cells per ml with either 5mgml
 1
Hoechst 33342 dye (Sigma, St Louis, MO, USA) or Hoechst dye
plus 100mM (þ/ ) Verapamil hydrochloride (Sigma) and
incubated such cells at 371C for 25min as described by us
previously (Kruger et al, 2006). These cells were further stained
with antibodies against Sca-1, c-Kit, ABCB1B or ABCG2 (BD
Pharmingen, San Diego, CA, USA), and the appropriate isotype
controls (BD Pharmingen). Then, 1 10
6 viable cells were analysed
and sorted by EPICSALTRA (Beckman Coulter, Fullerton, CA,
USA). The Hoechst dye was excited at 350nm, and its fluorescence
measured at two wave length (450/20nm band-pass filter and
675LP optical filter). Fluorescence-activated cell sorting (FACS)
data were analysed with FlowJo software (Tree Star, Ashland,
OR, USA).
Reverse transcriptase (RT)–PCR analysis
Total RNA from three independently sorted D121-SP and non-SP
cell samples was isolated using RNAeasy (Qiagen, Valencia, CA,
USA). The RNA from D121 cells was transcribed in cDNA using
the SuperScript First-Strand Synthesis System (Invitrogen).
RT–PCR was performed with SuperScript One-Step (Invitrogen).
Primers used were as follows: ABCG2 (sense, 50-TCCTCCCAGACT
TGGAAATG-30; antisense, 50-GGGTGTCTGTGGTAGGAGAA-30),
Sca-1 (sense, 50-TGGACACTTCTCACACTACAAAGTC-30;a n t i s e n s e ,
50-CAGAGCAAGGTCTGCAGGAG-30), Wnt-1 (sense, 50-ACCTGTT
GACGGATTCCAAG-30; antisense, 50-GCCTCGTTGTTGTGAAGG
TT-30), Wnt-2 (sense, 50-ATGAACGTCCCTCTCGGTGGAATCTGG
CTC-30; antisense, 50-TCATGTAGGCGTCGCCCAGTCGGCACTC
TT-30), Wnt-10a (sense, 50-GACTCCACAACAACCGTGTG-30; anti-
sense, 50-TGGGGAAGGGAAGAAGAGAT-30), SOX2 (sense, 50-ACC
AGCTCGCAGACCTACAT-30; antisense, 50-ATGGGCTCTGTGGTC
AAGTC-30), Oct 4 (sense, 50-AGCTGCTGAAGCAGAAGAGG-30;
antisense, 50-CCAATCAGCTTGGGCTAGAG-30), Notch1 (sense, 50-
TTGACGTCACTCTCCTGTGC-30; antisense, 50-ACACAGGTGCCA
TTGTTGAA-30), GAPDH (sense, 50-CATTGACCTCAACTACATG
G-30; antisense, 50-CACACCCATCACAAACATGG-30).
Immunohistochemical fluorescence staining
The D121 cultured tumour cells were initially stained with Hoechst
33342 dye for 25min at 371C. The cells were then washed twice
with cold PBS and stained with rabbit anti-mouse SOX2 or Oct
4 mAb (ABD Serotec, Kidlington, UK) and goat anti-rat IgG Alexa
568 (Invitrogen) as the secondary reporter reagent. Rabbit anti-
mouse Sca-1 or ABCG2 antibodies were purchased from Santa
Cruz (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Reactions were visualised with goat anti-rat IgG Alexa 488
(Invitrogen), and slides were analysed by fluorescence microscopy
(Olympus, Munich, Germany).
siRNA gene silencing
We used the siRNA gene Silencer system (Santa Cruz Biotechnol-
ogy, Inc.) to perform the SOX2 gene silencing in D121 tumour cells
by following the instructions provided by the manufacturer. The
results of SOX2 expression in D121 were verified by RT–PCR.
Migration assay
Transwell migration assays were performed with either SOX2
siRNA D121 or wild-type D121 tumour cells being harvested in
modified Boyden chambers (Transwell; Corning Inc. Lowell, MA,
USA). After 4hr incubation at 371C, the cells on the lower surface
of wells were fixed with 1% paraformaldehyde, stained with 1%
crystal violet, and counted.
Apoptosis assay
For apoptosis studies, we used the Annexin V FCAS assay kit
(eBioscience, San Diego, CA, USA) according to the manufac-
turer’s protocol. Hoechst 33342 dye was added 25min before
incubation with Annexin V to identify the SP or non-SP cell
populations. We also used the cleaved Caspas-3 antibody that was
conjugated with Alexa Fluor 488 (Cell signaling technology Inc.,
Danvers, MA, USA) to stain with either SP or non-SP, which were
detected with flow cytometry.
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sIn vivo tumour cell challenge
Groups of C57BL/6 mice (n¼4) were injected i.v. with either
1 10
5 D121 wild type or D121 SOX2 knockdown lung carcinoma
cells. All mice were killed 25 days after tumour cell challenge.
Statistical analysis
The statistical significance of different findings between experi-
mental groups was determined by the Student’s t-test. Results were
considered significant if two-tailed P-values were o0.05.
RESULTS
D121 non-small cell lung carcinoma cells contain a side
population (SP) with cancer stem cell properties
To identify CSCs among D121 lung tumour cells, SP cells were
isolated by staining with Hoechst 33342 dye and then subjected to
flow cytometry with bone marrow cells serving as a positive
control (Figure 1A, left). The SP was stained with Hoechst dye in
the presence of the Ca
þþ-channel blocker Verapamil hydrochlor-
ide to verify the specificity of the SP population (Figure 1A, right).
FACS analysis of the sample clearly defined a SP population that
constituted 1.84±0.2% within D121 tumour cells and 5.27±0.8%
within the mouse bone marrow sample. Incubation with Verapamil
significantly reduced the number of cells found within the SP to
0.13±0.01% in D121 tumour cells and to 0.26±0.04 in the bone
marrow. These results suggest that D121 lung tumour cells contain
SP of cells similar to that found within bone marrow. Moreover, to
demonstrate the immunogenicity of SP cells, we cultured D121
cells with INF-g (20ngml
 1 72h) and then stained with Hoechest
33342 to collect SP. Expression of MHC-class I antigen on SP cells
was detected with H-2K
b or H-2D
b antibodies on SP from D121
cells and was found upregulated by incubation with INF-g,
providing an important potential target cell for immunotherapy
(Figure 1B). Furthermore, we confirmed that such SP cells possess
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Figure 1 D121 non-small cell lung carcinoma cells contain a SP with cancer stem cell properties. (A) D121 lung cancer cells and mouse bone marrow
cells were stained with Hoechst 33342 to determine a dye effluxing SP. (B) The MHC-I antigen expression on D121-SP cells was upregulated by incubation
with INF-g.( C) The SP of D121 cells was sorted by flow cytometry after being stained with Hoechst 33342 dye, and a group of C57/BL mice were
implanted in the cleared fat pad with either the SP or non-SP fraction of D121 cancer cells at 1 10
5 per mouse. (D) All mice were killed on day 25 after
tumour cell implantation and analysed for the metastasis score on lungs.
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sstem cell features in vivo. In this regard, groups of C57/BL mice
(n¼8) were implanted i.v. with either SP or D121 lung cancer cells
(1 10
5 per mouse) (Figure 1C). All mice were killed on day 25
after tumour cell implantation, and lung metastasis score was
higher when applied to lungs of mice implanted with SP of D121
tumour cells than in mice implanted with non-SP control cells
(Figure 1D). All data suggest that only the SP cells of D121 lung
cancer cells contain the CSC fraction.
Upregulation of stem cell markers on D121-SP
To further establish the characteristics of SP cells among D121
tumour cells, we analysed for the expression of markers known to
be associated with stem or progenitor cells. To this end, we
performed flow cytometry, immunohistochemical fluorescence
staining and RT–PCR, respectively, to verify the expression of
Sca-1 and ABCG2 by different methods. We found expression of
ABCG2 and Sca-1 to be upregulated in the SP cells isolated from
D121 lung cancer cells when compared with that of non-SP derived
from these same cancer cells as detected by flow cytometry
(Figure 2A), by immunohistochemical fluorescence histology
staining (Figure 2B) and RT–PCR (Figure 2C). Together, these
results demonstrate that D121-SP cells express the stem cell
marker Sca-1 as well as the ABCG2 ATP-binding cassette
transporter, which is associated with resistance to multiple
chemotherapeutic drugs. These results support our contention
that D121-SP cells have a stem cell gene expression profile.
D121-SP cells reveal upregulation of stem cell-associated
transcription factors SOX2 and Oct 4
To determine which key transcription factors are involved in
maintaining stem cell characteristics we further analysed SP from
D121 cells for the expression of these important stem cell-
associated molecules. To this end, RT–PCR was performed to
determine expressions of SOX2, Oct 4, Notch-1 and Wnt-1, 2 and
Wnt-10a either in sorted SP or non-SP D121 cells. The results
indicated that expressions of SOX2 and Oct 4, but not those of
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Figure 2 Upregulation of stem cell markers on D121-SP population. (A) Expressions of ABCG2 and Sca-1 stem cell markers were upregulated in the
SP cells derived from D121 lung tumour cells as detected by flow cytometry, immunofluorescence histology staining (B) and RT–PCR (C).
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tumour cells when compared with those of non-SP cells
(Figure 3A). To further confirm these results, immunohistochem-
ical fluorescence staining was used with either anti-SOX2 or Oct 4
antibodies (Figure 3B). Our findings clearly indicated a markedly
higher expression of SOX2 and Oct 4 in D121-SP cells than that
observed in non-SP cells. These data suggest that the transcription
factor SOX2 together with its partner gene might have an impor-
tant role in the maintenance of tumour stem cell characteristics.
Downregulation of SOX2 gene expression results in
inhibition of migration and increased apoptosis of D121
lung carcinoma cells
To further explore SOX2 function in the SP of D121 tumour cells,
we applied the siRNA technology to knockdown SOX2 gene
expression. The expression of SOX2 at the RNA or protein level in
D121 lung tumour cells was found to be markedly downregulated
by siRNA as verified by western blotting and RT–PCR (Figure 4A).
We also found that expressions of TGF-b and Oct 4 were
downregulated when Sox2 was knocked down by siRNA
(Figure 4B). Furthermore, when we knocked down SOX2 expres-
sion in D121 cells with siRNA and then performed the cell
migration assay, we found a marked reduction of D121 cell
migration (Figure 4C). More interesting, the percentages of
D121-SP cells were markedly decreased after SOX2 downregulation
(Figure 4D). In addition, when FACS analysis was used to detect
apoptosis under these conditions, we observed a distinct increase
in apoptosis of SP cells that was demonstrated by Annexin V and
the expression of Caspase-3 in D121-SP cells (Figure 4E and F).
These results suggest that SOX2 gene expression in the SP derived
from D121 cancer cells could indeed have an important role in
maintaining CSC characteristics, and regulate a target gene such as
TGF-b that is able to control tumour progression and metastasis.
Therefore, SOX2 could possibly serve as a potential target for
improved treatment of lung cancer.
SOX2 knockdown in D121 lung carcinoma cells suppressed
experimental metastases in syngeneic C57/BL mice
To determine the effect of SOX2 knockdown in D121 cells on
inhibition of tumour growth and metastases in vivo, C57BL/6 mice
were injected i.v. with either 1 10
5 D121-SP wild type or D121-SP
SOX2 knockdown lung carcinoma cells. The data indicate that
tumour foci on the lung surface of mice (Figure 5A) or lung
weights (Figure 5B) of mice implanted with D121-SP SOX2 knock
down cells are significantly smaller than that in mice implanted
with wild-type D121-SP cells (Po0.001).
DISCUSSION
The cancer stem cell model of tumour development and
progression implies that tumours contain a subset of cells that
can both self-renew and give rise to a differentiated progeny
(Eaves, 2008). As in other tissues, stem cells are a minority
population of the whole organ, but are the only cells that can
maintain tumour growth indefinitely. The remaining cells, though
actively proliferating and making up the majority of cells in the
tumour, are also differentiating and destined to die. Consequently,
the self-renewal properties of CSCs are the real driving force
behind tumour growth. Hence, the limited number of CSCs in the
tumour and their specific phenotype are held responsible for
tumour cell escape from conventional cancer therapies, resulting
in disease relapse (Wegner, 1999; Graham et al, 2003). Thus, CSCs
have been identified in a variety of solid malignancies with the
identification of CSCs in these tumours being based on cell surface
markers such as CD24, CD44, CD133 and Sca-1 (Singh et al, 1990;
Al-Hajj et al, 2003; Xin et al, 2005). Cancer stem cells have been
isolated by their ability to efflux the lipophilic Hoechst 33342 dye
and are referred to as the ‘side population’.
In this study, we applied flow cytometry and the Hoechst
33342 dye efflux assay to isolate and characterize SP cells from the
murine D121 non-small cell lung carcinoma cell line. Our data
indicated SP cells to be enriched among D121 tumour cells when
compared with non-SP cells. In general, the SP of D121 tumour
cells is 1.8%, which displayed elevated expression of the ABCG2-
ATP-binding cassette transporters on the cell surface, indicative of
resistance to multiple chemotherapeutic drugs. Moreover, we
found for the first time that SP isolated from D121 tumour cells
express MHC-class I antigens when induced by exposure to IFN-g;
this might be of considerable importance for further eliciting
T-cell-mediated immune response against such cancer stem cells,
which could be critical for the development of effective cancer
immunotherapy.
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study, indicating that the SP, isolated from murine D121 lung
tumour cells by rapid Hoechst 33342 dye efflux, did exhibit
resistance to chemotherapy. Indeed, RT–PCR and ICF further
revealed an underlying molecular mechanism as the expression of
SOX2 was markedly upregulated in SP isolated from D121 non-
small lung cancer cells. The upregulation of such stem cell markers
as ABCG2 and Sca-1 in the SP population isolated from D121 non-
small cell lung cancer cells is also highly significant; especially as
these makers are associated with multiple drug resistance. This
finding correlates with the well-known function of chemoresis-
tance by cancer stem cells, due in part to their state of dormancy in
the G0/G1/phase of the cell cycle (Allan et al, 2006).
Our findings indicating that the SP population isolated from
D121 non-small cell lung cancer cells reveals upregulation of well-
known stem cell-associated transcription factors SOX2 and Oct 4.
Correlates with recent findings by others that these two transcrip-
tion factors form a heterodimeric molecular complex, which
controls a transcriptional regulator network that helps to
orchestrate the self-renewal and pluripotency of embryonic stem cells.
The siRNA-mediated knockdown of SOX2 in D121 lung
carcinoma cells, which led to the decisive inhibition of these cells’
migration in a transwell migration assay suggests that this
transcription factor may regulate key biological functions of these
cells. This contention was strengthened when we discovered by
FACS analysis that apoptosis of SP cells was markedly increased by
siRNA mediated knockdown of SOX2. Most importantly, we could
demonstrate that the downregulated expression of SOX2 in SP
achieved by siRNA knockdown did markedly decrease tumour
growth and metastasis of D121 non-small cell lung cancer cells. In
fact, the key role played by transcription factor SOX2 in this regard
was clearly indicated when D121 lung cancer cells, subjected to
SOX2 knock down in vitro, were subsequently injected i.v. into
syngenic C57BL/6 mice. Together, our findings suggest that the
SOX2 signalling pathway in CSCs derived from D121 lung cancer
cells is activated and has a key role in the development and
maintenance of cancer stem cells. Although the function of the
SOX2 signalling pathway as well as its downstream genes Oct 4 and
Nanog in the development and maintenance of cancer stem cells is
still being investigated, based on our experimental results, we
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Figure 4 Inhibition of migration and increased apoptosis of D121 lung carcinoma cells by downregulation of SOX2 gene expression. (A) The expression
of SOX2 in D121 lung cancer cells was downregulated by siRNA as verified by western blotting and RT–PCR. (B) Downregulation of TGF-b and Oct 4
while SOX2 expression of SOX2 was knocked down by siRNA. (C) Inhibition of D121 cells migration after downregulation of SOX2. (D–F) Increased
apoptosis of D121-SP cells, which was indicated by increasing Caspase-3 and Annexin V after SOX2 knockdown in D121 cells.
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stem cell development and that its deregulation can effectively
suppress growth and metastasis of non-small cell lung carcinoma
cells. This novel strategy may contribute to the future development
of efficacious cancer treatments.
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